Sadakatsu Ikeda

Also affiliated with The Cancer Institute Hospital

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 5 papers. Top paper: “Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity”.

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity

OncoImmunology(2020)10.1080/2162402x.2019.1708065

N/A

0.635DataRank · unranked

68 citations

Ryosuke Okamura, Yuichi Kumaki, Sadakatsu Ikeda, Mina Nikanjam, Ramez N. Eskander +9 more

Comprehensive Genomic Profiling of Circulating Cell-Free DNA Distinguishes Focal MET Amplification from Aneuploidy in Diverse Advanced Cancers

Current Oncology(2021)10.3390/curroncol28050317

N/A

0.425DataRank · unranked

16 citations

Steve Olsen, Mitsukuni Suenaga, Tsuyoshi Nakagawa, Hiroyuki Uetake, Sadakatsu Ikeda +1 more

KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery

The Oncologist(2021)10.1002/onco.13702

N/A

0DataRank · unranked

14 citations

Thomas McFall, Kenta Takahashi, Kasey Bamel, Sadakatsu Ikeda, Ramez N. Eskander +5 more

Efficacy of EGFR tyrosine kinase inhibitors in patients with non–small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry)

Lung Cancer(2025)10.1016/j.lungcan.2025.108479

N/A

0DataRank · unranked

0 citations

Hiroki Izumi, Ikei S. Kobayashi, Shingo Matsumoto, Yukio Hosomi, Takae Okuno +23 more

Tumor mutational burden, PD-1, negative Wnt/β-catenin regulators, and positive MHC class II antigen presentation regulators as predictors of longer survival after immune checkpoint inhibitors across cancers: A comprehensive analysis of 400 immunity biomarkers.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.2625

N/A

0DataRank · unranked

0 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +6 more